---
document_datetime: 2023-09-21 21:34:10
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mvasi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: mvasi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.3478084
conversion_datetime: 2025-12-24 16:03:37.261578
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MVASI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                  |
|----------------------|-----------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/403/2 02202    | Periodic Safety Update EU Single assessment - bevacizumab | 13/10/2022                          | 20/12/2022                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/403/202202. |
| R/0025               | Renewal of the marketing authorisation.                   | 21/07/2022                          | 21/09/2022                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of MVASI                  |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                                                              |            |            |             | in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                              |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0027           | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                             | 07/09/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                          |
| IB/0028           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 12/07/2022 | 21/09/2022 | SmPC and PL | Update of section 4.2 and 6.6 of the SmPC and section 3 of the package leaflet by adding 'Do not shake the vial'. The MAH also took this opportunity to make a small editorial correction to the contact details of the local representative in DE and aligned the annexes with the currently approved annexes of the reference product. |
| PSUSA/403/2 02102 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                    | 30/09/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                        |
| IB/0024           | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                   | 06/09/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                          |
| IB/0023           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 09/07/2021 | 08/07/2022 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| WS/2026   | for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method   | 08/07/2021   | n/a        |                       | This was an application   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|---------------------------|
| IB/0020   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                    | 11/05/2021   | n/a        |                       |                           |
| II/0017   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                       | 04/03/2021   | n/a        |                       |                           |
| IB/0019   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                           | 26/02/2021   | 21/04/2021 | SmPC, Annex II and PL |                           |
| IB/0018   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                          | 21/12/2020   | n/a        |                       |                           |

<div style=\"page-break-after: always\"></div>

| PSUSA/403/2 02002   | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/10/2020   | n/a        |                 | PRAC Recommendation - maintenance   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------------|
| IB/0016/G           | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 05/08/2020   | 15/09/2020 | SmPC and PL     |                                     |
| IB/0015             | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                        | 21/07/2020   | 15/09/2020 | SmPC and PL     |                                     |
| IAIN/0014           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/06/2020   | n/a        |                 |                                     |
| IA/0012             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/05/2020   | 15/09/2020 | Annex II and PL |                                     |
| T/0011              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/03/2020   | 01/04/2020 | SmPC,           |                                     |

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                                                                                                    |            |            | Labelling and PL   |                                   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------|
| IB/0010/G         | This was an application for a group of variations. C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication                                                                 | 07/01/2020 | 13/02/2020 | SmPC and PL        |                                   |
| IAIN/0009         | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                     | 30/10/2019 | 13/02/2020 | SmPC and PL        |                                   |
| II/0008           | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 12/09/2019 | n/a        |                    |                                   |
| PSUSA/403/2 01902 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                          | 05/09/2019 | n/a        |                    | PRAC Recommendation - maintenance |
| N/0006            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                   | 24/04/2019 | 13/02/2020 | PL                 |                                   |
| II/0005/G         | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting                                                                                        | 29/11/2018 | 06/02/2019 | Annex II           |                                   |

<div style=\"page-break-after: always\"></div>

|                   | material [-] used in the manufacture of a biological/immunological product B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |                 |                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/403/2 01802 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                                                                                       | 06/09/2018 | n/a        |                 | PRAC Recommendation - maintenance |
| IG/0946           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                          | 04/06/2018 | 06/02/2019 | PL              |                                   |
| IAIN/0001         | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                          | 12/02/2018 | 06/02/2019 | Annex II and PL |                                   |